Zhejiang Hisun Pharmaceutical Co., Ltd. announced that its controlling subsidiary Zhejiang Hisun Animal Health Products Co., Ltd. has received the New Veterinary Drug Registration Certificate for compound fipronil, praziquantel and moxidectin spot-on solution, approved and issued by the Ministry of Agriculture and Rural Affairs. The registration category is Category IV, and the certificate number is 2026 New Veterinary Drug Certificate No. 90. The product was jointly developed by Hisun Animal Health and two other companies, and is used for the prevention and treatment of internal and external parasite infections in cats, including fleas, ticks, heartworm, gastrointestinal nematodes, ear mites and sarcoptic mange. The company stated that the approval will help advance the strategic layout of its veterinary drug segment, but the product still needs to obtain a veterinary drug product approval number before it can be marketed, and it will not have a significant impact on business performance in the short term.
Zhejiang Hisun Pharmaceutical Co LtdControlling subsidiary Zhejiang Hisun Animal Health received a New Veterinary Drug Registration Certificate for a compound antiparasitic spot-on solution, advancing its veterinary drug segment.
The subsidiary obtained the New Veterinary Drug Registration Certificate for compound fipronil, praziquantel and moxidectin spot-on solution, though marketing still requires a product approval number.
